Nasdaq
$1.25▲ 2.46%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.0MShares out 8.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 8.13Pre-market26.08.13 20:258-KKey event#●●●#●●●
Cellectar Biosciences, Inc.
Cellectar Biosciences reported a net loss of $6.9 million, or $0.57 per share, for the second quarter of 2026, with $34.0 million in cash and cash equivalents as of June 30. The company has initiated site activation for the Phase 3 confirmatory trial of Iopofosine I 131, targeting an FDA New Drug Application submission in mid-2027, supported by capital raised in May 2026.…more
$1.25+2.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.13Pre-market26.08.13 20:0010-QEarnings
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. (CLRB) has filed its quarterly report (Form 10-Q) for the period ended June 30, 2026. The filing includes certifications from the CEO and CFO regarding the accuracy of the financial statements and the effectiveness of the company's internal controls over financial reporting.…more
$1.25+2.46%vs prev closeView filingShare - 8.4Regular26.08.04 23:06SCHEDULE 13GOwnership
Cellectar Biosciences, Inc.
Empery Asset Management, LP와 Ryan M. Lane은 Cellectar Biosciences, Inc.의 지분 보유 현황을 보고하는 Schedule 13G 공동 취득 성명서를 2026년 8월 4일자로 제출했다. 본 공시는 해당 투자 주체들이 공동으로 지분을 보유하고 향후 관련 보고 의무를 이행하기로 합의했음을 명시한다.…more
$1.25+2.46%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 20:00#●●●#●●●
Cellectar Biosciences Reports Positive Phase 2b Efficacy Data for Iopofosine I 131…more
Cellectar Biosciences announced positive efficacy results from a subset analysis of its Phase 2b trial for its Waldenström macroglobulinemia treatment candidate. The company plans to submit a New Drug Application for accelerated FDA approval in the first half of 2027.…more
$1.25+2.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29Pre-market26.09.29 20:30
●●●●●●●● ●●●●● ●●●●●●
Cellectar Biosciences will present positive Phase 2 subset analysis data for its Waldenström Macroglobulinemia treatment candidate at an upcoming international workshop. The company remains on track to submit a new drug application for accelerated approval in the first half of 2027.…more
$1.25+2.46%vs prev close - 8.13Pre-market26.08.13 20:15
●●●●●●●● ●●●●● ●●●●●●
Cellectar Biosciences announced the initiation of its Phase 3 confirmatory trial for iopofosine I-131, targeting an FDA accelerated approval submission by mid-2027. The company is leveraging recent capital raises to advance its oncology pipeline and maintain strong operational momentum.…more
$1.25+2.46%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report